Home
NewsNewsLuna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
On March 17, 2026, healthtech innovator Luna and fertility benefits provider Kindbody announced a strategic partnership aimed at transforming women’s health through enhanced data-driven Intelligence in Fertility Care. This collaboration is designed to provide unprecedented clarity and personalisation for individuals navigating the complexities of the fertility journey.
Luna, recognised for developing advanced smart wearables, will integrate its biomarker tracking technology into Kindbody’s comprehensive fertility and family-building platform. This integration addresses a critical gap in reproductive health: the fact that intricate physiological shifts, such as changes in temperature, recovery, sleep, stress, and hormonal rhythms, primarily occur outside of a doctor's office. By bringing these daily signals into focus, the partnership offers patients a deeper understanding of their own bodies while providing Kindbody’s clinical teams with a contextual, holistic view of each individual’s health.
Amit Khatri, Founder of Luna, emphasised the human element of this technological advancement. “The conception journey is one of the most meaningful and complex chapters in a person's life, and it deserves both deep empathy and deep intelligence,” said Khatri. “By uniting Luna's continuous biomarker sensing with Kindbody's world-class clinical expertise, we are giving patients a clearer window into their bodies and giving physicians a new dimension of insight that can elevate the entire care experience. This partnership represents the future of reproductive health: connected, personalised, and profoundly human."
Kindbody, which operates a national network of signature clinics and provides virtual care, offers a wide array of services, including IVF, egg freezing, donor care, and LGBTQ+ fertility support. The company’s mission is to make high-quality reproductive care more accessible and equitable. Through this partnership, Luna’s technology, including the Luna ring, will be made available within the Kindbody ecosystem to support patients seeking a more connected path toward parenthood.
David Stern, CEO of Kindbody, highlighted the clinical value of the collaboration. “This partnership with Luna represents a significant step forward in making fertility care smarter and more personalised," said Stern. “By leveraging data-driven insights, we can better support patients and providers alike, ensuring every decision is informed, effective, and centred on the needs of those on their fertility journey."
At the heart of Luna’s contribution is LifeOS, an adaptive health operating system that interprets data from the Luna Ring to deliver real-time guidance on energy, recovery, and women’s health. Kindbody continues to expand its reach, offering benefit solutions for employers and health plans while covering everything from menopause to male fertility and holistic well-being. Together, the two companies aim to move precision health from an aspirational concept to a standard of care.
Fairfax IVI expand donor sperm access through a strategic partnership that enhances availability, integrates donor services into fertility care, and supports diverse patient needs. With personalised guidance, genetic insights, and streamlined logistics, the collaboration aims to reduce barriers and deliver a more accessible, inclusive path to parenthood.
Sapyen and Avenues launch at-home fertility diagnostics, introducing a couple-first testing model in the UK. By integrating semen analysis and AMH testing into early care, this approach reduces clinic visits, accelerates diagnosis, and ensures balanced fertility evaluation, transforming how patients begin their reproductive health journey.
Nexpring Health has invested in May Health to accelerate the development of the Anavi™ System, a novel device designed to treat PCOS-Related Infertility. The technology aims to restore ovulation through a single office-based procedure, expanding treatment options for millions of women affected by polycystic ovary syndrome.
INVO Fertility would be introducing time-lapse incubation technology at its Wisconsin clinic, hence offering high-quality lab care, creative patient solutions, and advanced embryo monitoring for improved fertility results.
Costco, Sesame, and IVI RMA North America have announced strategic partnership to alter fertility care in the U.S. by removing biggest obstacles to care including high costs and limited access.
Carea has launched its Trying to Conceive - IVF/IUI mode to help women undergoing intricate fertility treatment with risks of inconsistent clinic continuity through continuous tracking and expert guidance.
